0.75
-0.0271(-3.49%)
Currency In USD
| Previous Close | 0.78 |
| Open | 0.81 |
| Day High | 0.83 |
| Day Low | 0.75 |
| 52-Week High | 1.31 |
| 52-Week Low | 0.56 |
| Volume | 416,688 |
| Average Volume | 489,140 |
| Market Cap | 31.47M |
| PE | -1.47 |
| EPS | -0.51 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 0.78 |
| Change | -0.03 |
If you invested $1000 in SCYNEXIS, Inc. (SCYX) 10 years ago, it would be worth $15.15 as of February 17, 2026 at a share price of $0.75. Whereas If you bought $1000 worth of SCYNEXIS, Inc. (SCYX) shares 5 years ago, it would be worth $80.21 as of February 17, 2026 at a share price of $0.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
GlobeNewswire Inc.
Jan 28, 2026 1:00 PM GMT
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutionsJERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a
SCYNEXIS Receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designations for SCY-247
GlobeNewswire Inc.
Jan 21, 2026 1:00 PM GMT
The QIDP designation will ensure at least 10 years of market exclusivity for SCY-247 following approval Recent articles highlight the growing threat from a rapidly spreading, multi-drug resistant, Candida auris fungal infection JERSEY CITY, N.J., Ja
SCYNEXIS Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
GlobeNewswire Inc.
Dec 22, 2025 1:00 PM GMT
JERSEY CITY, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it has receiv